OBJECTIVES: Benefits of treatment can be measured by utility values. Health utilities typically range between 0 (dead) and 1 (full health) and reflect health-related quality of life (HRQL) in a given health state. Societal values for health states can be captured using the time trade-off (TTO) methodology. Currently, no values exist for health states depicting stages of R/R HL and sALCL for Latin American countries. The aim of this study was to collect utility values from members of the public in Mexico and Brazil for R/R HL and sALCL health states. METHODS: Health states were developed using recognized methods, including a literature review, patient and clinician interviews, and cognitive debriefing. States included stages of R/R HL and sALCL (complete response [CR], partial response [PR], stable disease, and progressive disease), and adverse events (AEs) including B-symptoms, acute/chronic graft-versus-host disease (GVHD), and grade I/II or grade III peripheral sensory neuropathy (PSN). Members of the public in Mexico (n=100) and Brazil (n=101) valued each health state using the TTO methodology.  RESULTS: Participants showed a clear preference for the treatment response states; CR was valued as the state least likely to affect HRQL, with utility gains of 0.13–0.14 over stable disease. The experience of any AE was associated with a large decline in quality of life. The most burdensome AEs were acute GVHD and grade III PSN. Experiencing acute GVHD gave a disutility from stable disease of 0.190 (for Brazil) and 0.125 (for Mexico). Only minor discrepancies existed between the mean utilities for the two countries, the largest being for PR (Mexico, 0.633; Brazil, 0.717). CONCLUSIONS: Societal valuation of health states for R/R HL and sALCL revealed the notable perceived benefit of a treatment response and the significant disutility associated with AE experience. Utility values for Mexico and Brazil were broadly consistent.